Patient's Anastrozole Compliance to Therapy Programme

AstraZeneca4,923 enrolled

Overview

Approximately 60 specialised clinics and 420 office based gynaecologists or oncologists will participate in this in practice evaluation program (NIS). The clinic and approximately 7 office based physicians will collaborate within their breast centre networks to conduct this program. A breast centre network should be able to recruit in this program approximately 80 patients (approximately 40 patients per year). It is planned to enroll approximately 4674 patients in this NIS (2337 patients per arm). The patient population will include postmenopausal women with hormone-receptor positive primary breast cancer scheduled for upfront adjuvant endocrine treatment with anastrozole according to the current standard medical procedures.

Study Type

OBSERVATIONAL

Enrollment

4,923

Conditions

Breast Cancer

Interventions

AnastrozoleDRUG

oral

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological/cytological confirmed primary diagnosis of early breast cancer * Postmenopausal * Hormone receptor positive Exclusion Criteria: * Patients with severe renal function disorders * Patients with moderate or severe disorders of hepatic function * Concomitant treatment with drugs known to affect sex hormonal status and tamoxifen

Outcomes

Primary Outcomes

Compliance rate and persistence rate

Time frame: until discontinuation of treatment

Secondary Outcomes

Time to treatment discontinuation

Time frame: date of last intake of anastrozole minus date of first prescription of anastrozole + 1

Demographics and other baseline characteristics as well as information regarding concomitant medication, quality of life

Time frame: until treatment discontinuation

The percentage number of patients with disease free survival

Time frame: after 12 months

Time of disease free survival

Time frame: date of recurrence or progression of the tumor minus date of primary breast cancer surgery + 1